Catch up on the latest Unlocking Myasthenia Gravis (MG) podcasts. Hear Gilhus, Kaminski, Vissing & Wolfe discuss unmet needs, thymectomy decisions and tools shaping MG care. All episodes are in the MG hub on Medthority’s Rare Disease Nexus

To mark #InternationalPompeDay#, new survey data highlight persistent challenges in late‑onset Pompe disease care, from delayed diagnostic journeys to unmet supportive needs. Read the latest insights

This #InternationalPompeDay#, watch Benedikt Schoser, Priya Sunil Kishnani, and @MozaffarTahseen discuss unmet needs in late‑onset Pompe disease, now available on the NEW Medthority Rare Disease Nexus for expert insights and CME

Join me in donating to @BTWFoundation for #GivingTuesday#. Your donation will help support youth mental wellness and grassroots community organizations working to meet unmet needs for young people across the country. 💕

Join me and give to @BTWFoundation for #GivingTuesday#. We’re working hard to support youth mental wellness and collaborate with grassroots community organizations meeting the unmet needs for those most affected in these unprecedented times 💕

Enlivex $ENLV: Allocetra Phase 2b U.S. Enrollment Opens; Addressing 78 Million Patient Opportunity With No Competing Disease-Modifying Therapies Knee osteoarthritis is one of the most prevalent disabling conditions in the world, and it remains entirely without an approved disease-modifying treatment. Enlivex is now enrolling patients in the United States as part of its global Phase 2b trial of Allocetra™, an allogeneic, off-the-shelf cell therapy engineered to reprogram macrophages back toward their homeostatic state. The rationale for Allocetra™ is grounded in the current scientific understanding that disrupted macrophage function drives the chronic inflammation that underpins osteoarthritis progression — a mechanism distinct from everything currently in the standard-of-care toolkit. Key Investor Takeaways: • Unmet Need is Structural: 32 million Americans affected today, 78 million projected by 2040, and currently pain relief and surgery are the only tools available. • Six-Month Efficacy Data on the Horizon: Primary endpoints measure pain and physical function changes from baseline at three and six months post-treatment. • Clinical Momentum is Real: Positive Phase 1 & Phase 2a results in the same patient population • Platform Applicability: Positive Phase 2b data would support Allocetra's macrophage modulation potential across a broader range of inflammatory and autoimmune conditions. Read the full announcement: $ENLV $RAIN $MSTR $MARA $TSLA $SMLR $COIN $FORD $HIVE $EXOD $JNJ $ABBV $MRK

Philanthropy is at the heart of Bloomberg culture. 👐❤️ Together with @BloombergDotOrg and Bloomberg Service, we're proud to give back this Giving Tuesday—and every day. With over 160,000 volunteer hours so far this year, Team Bloomberg is making a difference. From preparing meals to building homes, employees around the world are taking action to address unmet needs in communities worldwide. 🌎 #TeamBloomberg# #GivingTuesday# #ImpactinAction#

BioVie $BIVI: SUNRISE-PD Phase 2b Trial Completes Last Patient Visit — Topline Parkinson's Data on Track for Q3 2026 $BIVI has completed the final patient evaluation visit in its SUNRISE-PD Phase 2b trial, a 57-patient, randomized, double-blind, placebo-controlled study evaluating bezisterim in early-stage Parkinson's disease patients who have not yet been treated with carbidopa/levodopa. The company is now entering the study closeout process, with topline results expected in Q3 2026. SUNRISE-PD was specifically designed to quantify the magnitude of bezisterim's therapeutic impact on motor function, sleep disorder, anxiety, depression, and cognitive slowness, with the explicit goal of finalizing the design for Phase 3 registrational trials. This readout is the blueprint decision point for the path to potential approval. In prior clinical work, bezisterim has shown signals of improved motor control, reduced neuroinflammation, and improved "morning on" symptoms in Parkinson's patients. Why Investors Should Be Watching: • Topline data catalyst in Q3 2026 • Results are designed to inform Phase 3 registrational trial design — this is a structural milestone, not just a data point • Bezisterim targets TNFα-mediated inflammation and insulin resistance, a differentiated mechanism in a disease space with significant unmet need • A recent KOL event featuring a Brown University neuropathologist reinforced the scientific rationale behind bezisterim's approach to neurodegeneration • Long COVID Phase 2 topline data also expected Summer 2026, providing a second near-term catalyst For investors tracking $BIVI, Q3 2026 is shaping up as a defining period — one readout that could set the Phase 3 course for bezisterim in Parkinson's, and a second from the Long COVID program arriving around the same time. Read the full announcement: $BIVI $SXTP $INAB $DMAC $BFRG $NSRX $CLDI $NXL $CNTB $LTRN $KYNB $ANIX